Infectious Diseases Consultation Platform 2022

Roger Paredes, MD, PhD, is the Head of the Infectious Diseases Service at Hospital Universitari Germans Trias i Pujol, Head of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, Badalona, Spain.

Roger Paredes obtained an MD, PhD degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB). He specialised in HIV resistance at the Brigham & Women’s Hospital in Boston and Harvard Medical School. His team has demonstrated the clinical utility of HIV-1 deep sequencing in both high- and low-income countries.

Eugènia Negredo completed the specialty of Internal Medicine at the Sant Pau Hospital, Barcelona, in 1998. She received her Ph.D. in Medicine from the Autonomous University of Barcelona, in 2002. Since 1999, Dr. Negredo works as a physician in the HIV Unit of Germans Trias i Pujol Hospital in Barcelona, and she leads the research group focused on the epidemiology, pathogenesis and treatment of different HIV- and antiretroviral-related complications. She is also Associate Professor of Universitat Autònoma de Barcelona and Universitat de Vic.

Section Head of Infectious Diseases Department at University Hospital Germans Trias i Pujol. Investigator Member of CIBERes and AGAUR.

Dr. Pedro-Botet is specialized in Infectious Diseases, Respiratory Infections and Legionella. She is currently Professor and Chair of Medicine and a member of the Grade of Medicine Committee at the Autonomous University of Barcelona’s School of Medicine. She has been Principal or co-Investigator of 10 projects funded either by national or international grant agencies. Author of 91 papers in peer-reviewed journals.

Born in Lleida in 1977, Beatriz Mothe, MD, PhD, completed under a national competitive post-specialization programme for physicians (ISCIII Rio Hortega CM08/00020 2009-2011) was on the subject of immunological, virological and genetic HIV-control mechanisms that could be incorporated into the rational design of novel therapeutic vaccine candidates (Catalan Award for Best Thesis on Infectious Diseases in 2012). She has actively participated in pre-clinical testing of a novel HIV T-cell immunogen called HTI, designed to redirect cytotoxic T-cell responses to protective and conserved HIV targets capable of controlling viral replication. Following US research stays at the Ragon Institute of MGH, MIT and Harvard (formerly Partners AIDS Research Center) and the National Cancer Institute at Frederick, after taking up a research fellowship position (ISCIII Joan Rodés JR13/00024 2014-2016), she is currently an associated researcher at the Host Genetics and Cellular Immunology group led by Dr. Brander in IrsiCaixa. She also works in the HIV unit of the Germans Trias i Pujol University Hospital, where she co-directs with Dr José Moltó the research line of Vaccines, Immunotherapies and Pharmacology. As a clinical researcher, she focuses on identifying and monitoring acute/recent HIV infection and HIV controllers as models for a functional cure (principal investigator for the early-cART and controller cohorts). She also coordinates clinical trials and immune monitoring in aspects related to therapeutic vaccines and eradication strategies. Mothe has been a teacher of the MSc in Zoonoses and One Health (UAB) since 2016 and is currently co-directing with Dr Brander a doctoral thesis on the subject of advanced immunology for the Autonomous University of Barcelona (UAB). She has been an associate professor in the Faculty of AIDS and Related Diseases at the University of Vic-University of Central Catalonia (UVic-UCC) since 2014.

Josep M Llibre, MD, PhD, received his MD in the Universitat de Barcelona, and obtained his specialty in Internal Medicine and his PhD in the Universitat Autònoma de Barcelona. He is a member of the panel of Antiretroviral treatment guidelines at the GeSIDA group (AIDS group of the SEIMC Spanish society), and an expert advisor of the Catalan Health Institute (ICS) on antiretroviral treatment and hepatitis C (PADEICS). He started caring for patients with HIV/AIDS at the beginning of the epidemic in Spain in 1987. His main areas of interest in HIV Medicine include the clinical implications of HIV-1 resistance, the analysis of safety and efficacy in HIV-1 antiretroviral treatment clinical trials (both in naïve and pre-treated patients), with a special interest in drug efficacy and pharmacoeconomics, and hepatitis C co-infection. He has published widely in journals and book chapters, as well as HIV/AIDS medical webs, on clinical aspects of HIV-1 treatment and care, HIV-1 resistance, clinical reviews, positioning papers, treatment intensification and simplification strategies, and participated in many pivotal clinical trials. He has also published in basic science research journals. He collaborates as an editor and/or peer-reviewing with many top international medical journals. He is involved in HIV Medical Educational training in Spain and other European, as well as Asian Countries.

Long COVID-19 director. Member of the Infectious Diseases Unit. She is responsible for a monographic consultation on congenital immunodeficiencies and her research is part of the lines of the Infectious Diseases Unit. She is an associate professor of Medicine at the UAB and tutor for internships and seminars in Physiopathology and Clinical Semiology and Biological Basis of Pathology for the UAB Medicine Degree at the Can Ruti Campus.

He completed his specialty at the Hospital Universitari Germans Trias i Pujol, with a stay at the Infectious Diseases service of the La Pitié-Salpêtrière University Hospital in Paris-France. At the end of his specialty, he oriented his clinical practice to the treatment of infectious pathologies, mainly HIV-infected patients and associated pathologies, as well as infectious pathologies that are difficult to manage.

For more than 7 years, he dedicated himself to the study of pathologies related to Human Papilloma Virus (HPV) infection in the HIV-infected population, a field in which he completed his doctoral thesis, finishing it in 2019. He obtained his degree in doctor of medicine with the highest qualification (Cum laude) for the publications he made in the field of prevention of anal cancer related to HPV infection, being the main author of the first publication worldwide that demonstrated the usefulness of anoscopy resolution as a prevention strategy for anal cancer.

During the COVID-19 epidemic, he led the first study that demonstrated the usefulness of screening with antigen tests to be able to carry out massive cultural events during the concerts of Love of Lesbian and the Sala Apolo in Barcelona, ​​events that had a great impact worldwide. and that their results were published in the prestigious journals Lancet ID and Annals of Internal Medicine.

Dr. Revollo has worked for three years as a volunteer with the NGO Médecins Sans Frontières - France in different countries on the African continent such as the Democratic Republic of the Congo, the Central African Republic, Tchad, Sudan, always orienting his clinical practice towards the treatment of infectious pathologies.

José-Ramon Santos MD, PhD, is a specialist in Internal Medicine and Infectious Diseases since 2005. He has focused most of his work on the study of HIV resistance to antiretrovirals and simplification strategies. He has co-authored multiple students nationally and internationally and has published in recognized journals (eg Clinical Infectious Diseases, PlosOne, Journal of Antimicrobial Chemotherapy). Since the appearance of the SARS-CoV-2 pandemic, it has also been involved in research and direct care of patients hospitalized for SARS CoV-2. In this sense, it has been achieved in some of the main studies carried out with (Beigel et al. N Engl J Med 2020 November 5th; 383 (19): 1813-182, Beigel et al. N Engl J Med 2020 May 225;383(19):1813-1826, Kalil et al. N English J Med 2020).

He is currently collaborating with groups studying reinfections by SARS-CoV-2 and long-COVID. Additionally, it has contributed to the preparation of the “Recommendations for the selection of the donor for the transfer of fecal microbiota. Position document endorsed by the Catalan Society of Digestology, the Catalan Society of Infectious Diseases and Clinical Microbiology and the GEMBIOTA group of the Spanish Society of Infectious Diseases and Clinical Microbiology”. In this same sense, it has succeeded in drawing up the protocol for carrying out microbiota transfer at the Germans Trias i Pujol Hospital and in successfully carrying out the same in said center.

José Moltó is clinical physician in the HIV Clinic of the Hospital Universitari Germans Trias i Pujol in Badalona, Spain. He obtained is MD from the University of Alicante in 1996, and completed his internal medicine training in the Hospital General Universitario de Elche (Alicante). Since his very early medicine studies, Dr. Moltó was interested in infectious diseases, particularly in HIV infection. He joined the HIV Clinic of the Hospital Universitari Germans Trias i Pujol in 2002, and he obtained his PhD degree from the Universitat Autònoma de Barcelona in 2008. He is committed with HIV research with special interest in clinical pharmacology of antiretroviral treatment, including population pharmacokinetics and drug-drug interactions.